702 related articles for article (PubMed ID: 18997742)
1. FDA cracks down on labeling, initiates trial result reporting.
Osborne R; Waltz E
Nat Biotechnol; 2008 Nov; 26(11):1203-4. PubMed ID: 18997742
[No Abstract] [Full Text] [Related]
2. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense.
Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ
Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421
[No Abstract] [Full Text] [Related]
3. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
4. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
[No Abstract] [Full Text] [Related]
5. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
6. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
7. Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
Anderson SJ
J Clin Oncol; 2006 Aug; 24(24):3821-2. PubMed ID: 16921032
[No Abstract] [Full Text] [Related]
8. FDA to tighten labeling on long acting opioids.
McCarthy M
BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
[No Abstract] [Full Text] [Related]
9. The learned intermediary doctrine: past, present and future.
Alsobrook HB
Leg Med; 1994; ():269-80. PubMed ID: 7830482
[No Abstract] [Full Text] [Related]
10. Regulatory experts debate FDA's authority.
Young D
Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
[No Abstract] [Full Text] [Related]
11. Red sky in the morning: modifying prescription drug labels as a result of postmarket surveillance.
Jacobson JD; Feigal D
Food Drug Law J; 2007; 62(3):529-46. PubMed ID: 17915395
[No Abstract] [Full Text] [Related]
12. Medical device vigilance at FDA.
Gross TP; Kessler LG
Stud Health Technol Inform; 1996; 28():17-24. PubMed ID: 10164091
[TBL] [Abstract][Full Text] [Related]
13. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
14. Making clinical data widely available.
Kaiser J
Science; 2008 Oct; 322(5899):217-8. PubMed ID: 18845745
[No Abstract] [Full Text] [Related]
15. Vioxx's history and the need for better procedures and better testing.
Gilhooley M
Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
[No Abstract] [Full Text] [Related]
16. FDA's regulation of prescription drug labeling: a role for implied preemption.
Kendrick LC
Food Drug Law J; 2007; 62(1):227-47. PubMed ID: 17444031
[No Abstract] [Full Text] [Related]
17. Safety-related drug labeling changes approved by FDA.
White GG
J Toxicol Clin Toxicol; 1998; 36(3):265-7. PubMed ID: 9678979
[No Abstract] [Full Text] [Related]
18. Public registration of clinical trials.
Steinbrook R
N Engl J Med; 2004 Jul; 351(4):315-7. PubMed ID: 15269307
[No Abstract] [Full Text] [Related]
19. The case for preemption of prescription drug failure-to-warn claims.
Kim CH
Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
[No Abstract] [Full Text] [Related]
20. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
